[Form 4] Kindly MD, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Jared Barrera, Chief Financial Officer of Kindly MD, Inc. (NAKA), reported a restricted stock award that fully vested on 09/22/2025, resulting in an acquisition of 6,400 shares at no cash price and increasing his beneficial ownership to 22,242 shares. The Form 4, filed by attorney-in-fact on 09/24/2025, shows the transaction was an internal equity award rather than an open-market purchase or sale. The filing includes a standard Exhibit 24 power of attorney signature and does not disclose any cash consideration, option exercises, or derivative transactions.

Positive

• Restricted stock award fully vested, aligning the CFO's interests with shareholders by increasing equity ownership
• Beneficial ownership rose to 22,242 shares, reflecting greater executive stake in the company
• Form 4 filing appears complete with Exhibit 24 power of attorney and signature, meeting disclosure requirements

Negative

• None.

Insights

Financial Analyst

TL;DR: Insider equity vesting increased the CFO's stake to 22,242 shares; this is a routine compensation event with limited immediate market impact.

The Form 4 discloses a fully vested restricted stock award of 6,400 shares to the CFO, which raises his direct holdings to 22,242 shares. Because the shares were awarded as restricted stock with a $0 reported price, this reflects compensation vesting rather than a cash transaction or market activity. For investors, such vesting aligns executive incentives with shareholder value but does not by itself signal new capital flows, debt changes, or operational shifts. No derivative activity or dispositions are reported.

Corporate Governance Expert

TL;DR: The filing documents a standard vesting of restricted stock to a named officer; it is a governance/compensation disclosure, not a governance concern.

The disclosure is concise and procedurally complete: it identifies the reporting person as CFO, the vesting date, the number of shares vested, and the resulting beneficial ownership. The inclusion of Exhibit 24 and a signed power of attorney indicates proper filing authority. There are no indications of unusual timing, related-party transfers, or immediate sales following vesting that would raise governance flags.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Barrera Jared

(Last) (First) (Middle)

5097 SOUTH 900 EAST, SUITE 100

(Street)

SALT LAKE CITY UT 84117

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kindly MD, Inc. [ NAKA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/22/2025		A		6,400(1)	A	$0	22,242	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This reflects a restricted stock award that was fully vested as of September 22, 2025.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Kyle Simon, as attorney-in-fact	09/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Jared Barrera disclose on the Form 4 for Kindly MD (NAKA)?

He disclosed a restricted stock award of 6,400 shares that fully vested on 09/22/2025, increasing his beneficial ownership to 22,242 shares.

Was there a cash purchase reported in this Form 4?

No. The transaction is reported with a $0 price, indicating vesting of awarded restricted stock rather than a cash purchase.

Does the Form 4 show any derivative transactions or sales by the CFO?

No. Table II (derivatives) shows no entries, and there are no reported dispositions or sales in Table I.

When was the Form 4 filed for this transaction?

The filing shows the transaction date as 09/22/2025 and the Form 4 was signed and filed on 09/24/2025 by attorney-in-fact.

What is the reporting person's role at Kindly MD?

The reporting person, Jared Barrera, is identified as the company's Chief Financial Officer (CFO).